Asymmetric Dimethylarginine: a Novel Cardiovascular Risk Factor in End-stage Renal Disease

Author： Alsagaff M Yusuf   Thaha M   Aminuddin M   Yogiarto RM   Yogiantoro M   Tomino Y  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.40, Iss.1, 2012-01, pp. : 340-349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD)

By Zoccali Carmine   Mallamaci Francesca   Tripepi Giovanni  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 131-135

Springer Publishing Company

Access to resources Recommend Favorite

Epidemiology of end-stage renal disease

By Roderick Paul  

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite

Anorexia in end-stage renal disease: pathophysiology and treatment

By Alvarez Vicente   Diéz Juan Jose   Aguilera Abelardo   Selgas Rafael   Codoceo Rosa   Bajo Maria A  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 11, 2001-11 ,pp. : 1825-1838

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K   Zussman B   Miller AK   Freed MI  

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Approach to the management of end-stage renal disease

By Rodger R Stuart C  

Clinical Medicine, Vol. 12, Iss. 5, 2012-10 ,pp. : 472-475

Royal College Of Physicians

Access to resources Recommend Favorite